Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice
American Journal of Physiology-Gastrointestinal and Liver Physiology · 2025
DOI: 10.1152/ajpgi.00272.2025 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Physiology-Gastrointestinal and Liver Physiology, 2025. Verfasst von Yuanqing Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, University of Florida, Gainesville, Florida, United States. Hauptthemen laut MEDLINE: Pioglitazone, Autophagy, AMP-Activated Protein Kinases, alpha 1-Antitrypsin Deficiency. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, Alpha-1 Foundation (A1F), HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB).
Abstract (Originalsprache)
α-1 Antitrypsin deficiency (AATD)-mediated liver disease lacks therapies that reduce hepatic ZAAT accumulation and liver manifestations. We demonstrate that pioglitazone activates AMPK and induces autophagy, leading to decreased ZAAT and improved proteostasis in Pi*Z mouse livers and human hepatocyte models. As an FDA-approved drug with metabolic benefits, pioglitazone holds promise for repurposing in AATD-related liver disease. These findings offer a mechanistic rationale for targeting autophagy to alleviate hepatic injury in protein misfolding disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, University of Florida, Gainesville, Florida, United States.
- Division of Pulmonary, Critical Care & Sleep Medicine, Department of Medicine, University of Florida, Gainesville, Florida, United States.
- Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Florida, Gainesville, Florida, United States.
- Department of Biochemistry and Molecular Biology, University of Florida, Gainesville, Florida, United States.
ORCID-Profile: Chalermchai Khemtong, Kenneth Cusi, Mark Brantly, Nazli Khodayari
Förderung
- NIBIB NIH HHS
- Alpha-1 Foundation (A1F)
- HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Zitieren
APA
Lu, Y., Oshins, R., Maptue, N. R., Shen, Q., Khemtong, C., Cusi, K., Brantly, M., & Khodayari, N. (2025). Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. https://doi.org/10.1152/ajpgi.00272.2025
Vancouver
Lu Y, Oshins R, Maptue NR, Shen Q, Khemtong C, Cusi K, et al. Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice. American Journal of Physiology-Gastrointestinal and Liver Physiology. 2025. doi:10.1152/ajpgi.00272.2025
BibTeX
@article{Lu2025,
author = {Lu, Yuanqing and Oshins, Regina and Maptue, Nesmine R and Shen, Qingyang and Khemtong, Chalermchai and Cusi, Kenneth and Brantly, Mark and Khodayari, Nazli},
title = {Pioglitazone reduces hepatic α-1 antitrypsin accumulation through autophagy and AMPK activation in α-1 antitrypsin-deficient mice},
journal = {American Journal of Physiology-Gastrointestinal and Liver Physiology},
year = {2025},
doi = {10.1152/ajpgi.00272.2025}
}
EUVIMED